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Abstract
Background: To compare abdominal hysterectomy, the most currently used for treating cancer of the
endometrium, to the vaginal hysterectomy in term of survival, morbidity and failure rates.
Methods: We retrospectively analyzed 68 cases divided into two sub-groups. A study group of 31 cases received
vaginal surgery; a control group of 37 cases was treated with a laparotomy. Mean operative time, median hospital
stay, intra- and post-operative complications, DFS and OS time as well as occurrence of local or distant recurrences
have been evaluated and reported. Cases included patients with a higher rate of medical morbidities (p = 0.01)
than controls.
Results: Mean age was 76.2 and 70.4 years in the vaginal (V) group and abdominal (A) group respectively. Mean
operative time was longer for the group A. Group V patients had a lower mean post-operative hospital stay (p <
0.05). Differences in the two groups regarding intra- and post-operative complications, occurrence of local or
distant recurrences and DFS time were not statistically significant. Disease specific survival time at 5 years scored
97% for group V, and 97% for group A.
Conclusions: Results show how vaginal approach had a similar outcome in selected patients. Vaginal surgery
could therefore be the proper choice in patients with early stages and lower surgical risk, in addition to elderly
patients exposed to a higher surgical risk.
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Background
Endometrial carcinoma is the most common gynecologi-
cal malignancy in western countries with an incidence of
15-20 per 100.000 women per year. In 2006, 41200 new
cases were reported only in the United States with half
of cases occurred in women older than 65 years [1].
Population aging is a major concern regarding this
tumor. In 2030, 20% of the US population will be older
than 65 [2]. This will increase the number of women
affected by endometrial cancer, with a consistent raise
of new cases per year. Among these new cases, elderly
patients will play a major role in the statistics.
The current gold standard for endometrial cancer
treatment is hysterectomy with BSO as well as perito-
neal washing and pelvic and para-aortic lymphadenect-
omy, performed either thru a laparotomy (the majority
of cases) or a laparoscopy. This is been performed
according to FIGO revised surgical and pathologic sta-
ging [3,4].
Several prognostic factors have been identified. Tumor
histology, stage and patient age seem to play an impor-
tant role in survival [5].
Morbidities like cardiovascular disease, diabetes melli-
tus and obesity are frequent in the elderly. When they
are concurrent to endometrial cancer, they raise surgical
morbidity and mortality rates. Nevertheless, surgery is
still mandatory for endometrial cancer staging and treat-
ment [6].
According to literature, higher age at the time of sur-
gery is associated to a worst prognosis. This evidence
relates certainly to the fact that older patients have a
higher chance to be under-treated, since their medical
conditions do not allow a major surgery required to
extirpate the tumor [7]. A less-invasive surgical
approach appears to be the best choice among this
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form a procedure that assures equivalent cure rates.
Avoiding a major abdominal surgery and general
anesthesia is highly remarkable. Less invasive
approaches as laparoscopy have today shown an evi-
dence-based equal treatment efficacy for early stages.
Key-hole surgery allows a shorter recover and lower
post-operative morbidity [8]. Nevertheless, these proce-
dures could be often severely contra-indicated in endo-
metrial cancer patient, since they require a general
anesthesia, which is contra-indicated in endometrial
cancer patients with frequent and concurrent morbid-
ities. These results show how vaginal approach had a
similar outcome in selected patients.
We compared the clinical outcome of the vaginal ver-
sus the abdominal hysterectomy in a population of
elderly patients as treatment for endometrial cancer at
an early stage. Morbidity, mortality, rates of recurrence,
disease-free survival (DFS) and overall survival (OS)
rates were evaluated and compared in both groups. The
primary objective of the study was to evaluate the role
of vaginal hysterectomy in elderly women with endome-
trial carcinoma.
Materials and methods
We retrospectively reviewed a series of women older
than 70 years who had a diagnosis of FIGO stage I or
stage II endometrial endometrioid adenocarcinoma.
These patients were consecutively treated at our center
from April 2002 to June 2006. Unfavorable histologies
were excluded from the series.
Two groups were identified. A first group (group V)
included medically compromised women undergoing
vaginal hysterectomy for cancer. A second group (group
A) included patients who underwent abdominal surgery
for cancer.
Group V considered patients with risk factors for sur-
gery as hypertension (systolic pressure > 140 mmHg
and/or diastolic pressure > 90 mmHg or patients treated
with antihypertensive drugs), diabetes mellitus (basal
glycemia > 140 mg/dL or patients treated with insulin
or oral therapy), obesity (BMI > 30 kg/m2), massive
obesity (BMI > 40 kg/m2), cardiovascular diseases (his-
tory of coronary artery disease (CAD), acute myocardial
infarction, heart failure, transient ischemic attack (TIA)
or stroke), respiratory diseases (obstructive or restrictive
patterns). Controls had, on the other hand, an apparent
good medical status.
Use of American Society of Anesthesiology (ASA)
classes assessed surgical risk; cases were included in
ASA class IV. Group V patients were considered unfit
to general anesthesia at the anesthesiologist evaluation.
Patients were clinically staged by chest X-rays, abdo-
mino-pelvic computed tomography (CT) scans or whole
abdomen magnetic resonance imaging (MRI), and trans-
vaginal ultrasound (US).
A pre-operative histological diagnosis of endometrial
cancer was obtained in both groups on endometrial
biopsy specimens.
Group V patients underwent a total vaginal hysterect-
omy with bilateral salpingo-oophorectomy at a time that
included a vaginal margin being at least 1,5 and maxi-
mum 2 cm. Anesthesiologists always performed a spinal
anesthesia.
Group A was treated with abdominal hysterectomy
with the same vaginal margin extension as above, bilat-
eral salpingo-oophorectomy, peritoneal washing and pel-
vic and para-aortic node dissection. A general anesthesia
was performed in all group A cases.
All the cases (both groups) who showed a high grade
(grade 3), deep myometrial invasion (> than a half) or a
FIGO stage II at histology were addressed to adjuvant
radiotherapy.
Mean operative time, mean hospital stay, intra- and
post-operative complications, DFS and OS time and the
occurrence of local or distant recurrences were then
evaluated.
Follow-up protocol included: recto-vaginal examina-
tion, Pap smear from the vaginal cuff, total body CT
scans every 6 months; chest X-rays and mammography
on a yearly basis.
Mean follow-up was 45 months for group V (range
36-70), and 49 months for group A (range 36-72). A fol-
low-up time of 36 months was considered valid accord-
ing to literature’se v i d e n c et h a tc o n s i d e r sah i g h e rr i s k
of recurrence during the first 3 years that follow surgery
[9].
Data are expressed as mean ± standard deviation.
Non-parametric Mann-Whitney test, or c2t e s tw e r e
used to compare data. Survival curves were plotted by
means of Kaplan Meier method and compared by using
the Log rank test. A p value lower than 0.05 was consid-
ered to be statistically significant
Results
68 cases older than 70 years with a diagnosis of endo-
metrial cancer were eligible for our study: 31 had vagi-
nal surgery (group V); 37 underwent abdominal surgery
(group A).
Vaginal surgery was performed in 45.6% (31/68) of
patients, abdominal surgery in 54.4% (37/68). Group V
patients’ age range was 70-86 years, with a mean age of
76.2 years and a median of 74 years. Group A range was
66-84 years, with a mean age of 70.4 years and a median
of 70 years.
Cases had a significant higher prevalence of co-mor-
bidities (p = 0.01), obesity (p = 0.02) and cardiovascular
disease (p = 0.04) (table 1).
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Page 2 of 656 patients (82%) presented at least one co-morbidity.
16 patients in the V group had three, or up to three risk
factors. Only 3 patients showed a similar condition
among controls.
All patients from group V had a spinal anesthesia.
Mean operative time was 78 minutes (range 55-110)
whether mean hospital stay was 6.6 days (range 5-10).
Group A patients had all general anesthesia. Mean opera-
tive time was 131 minutes (range 115-200) whether mean
hospital stay was 7.9 days (range 6-20) (table 2). 2
patients (2.9%) had intra-operative bleeding. One patient
was from the V group, the other among group A.
6 patients (8.8%) experienced post-operative complica-
tions. In the V group, 2 patients developed a pelvic
infection, in 1 patient a post-operative bleeding
occurred. The A group counted 3 patients who had,
respectively, bleeding, lymphorrea and deep venous
thrombosis (table 3). No peri-operative deaths occurred.
Distribution for stage, grade and myometrial depth
invasion between groups is reported in table 4.
Patients submitted to adjuvant pelvic radiation therapy
and vaginal brachytherapy were 6 (19%) with FIGO
stage IC and 1 (3%) with FIGO stage II tumors, all from
the V group.
All group A patients received pelvic and para-aortic
node dissection. The mean number of pelvic/aortic
nodes harvested was 11.5 ± 9.7 (1-34). No node metas-
tases were found at histologic examination.
Among group A, 11 (30%) patients with FIGO stage
IC tumors and 3 (8%) patients with stage II underwent
adjuvant pelvic RT and vaginal brachytherapy.
During follow-up, 9 cases showed recurrences, which
caused 2 patients to die of the disease. 2 (6%) patients
from group V had local recurrence after 18 and 25
months, respectively, whether group A showed local
recurrences after 26 and 58 months in 2 (5%) cases.
Distant recurrences occurred in 2 (6%) patients in
vaginal surgery group after 12 and 35 months. Abdom-
inal surgery group counted 3 (8%) cases after 6,12 and
18 months. 1 disease-related death (3%) and 3(9%)
deaths from other causes occurred in the V group.
Group A included 1(3%) death disease-related and 3(8%)
deaths from other causes.
5-years overall survival (OS) was 82% and 87% for
group A and V respectively (NS) (Figure 1). Disease-free
survival (DFS) at 5-years was 83% and 87% for group A
Table 1 Data related to comorbidity in two groups of
patients
Abdominal surgery
(n = 37)%
Vaginal surgery
(n = 31)%
p value
CV disease 16.2(6) 51.6(16) 0.004
Hypertension 54.1(20) 74.2(23) NS
DM 16.2(6) 25.8(8) NS
Obesity 10.8(4) 51.6(16) 0.002
Other 48.6(18) 64.5(20) NS
NS non significant: p > 0.05
Table 2 Data related to hospital stay and operative time
in two groups of patients
Abdominal surgery
(n = 37)%
Vaginal surgery
(n = 31)%
p value
Anesthesia
general 100 - < 0.005
spinal - 100 < 0.005
Hospital stay
(mean time)
9.1(± 2.6SD) 6.6((± 1.3SD) < 0.005
Median operative
time(min)
131 (115-200) 78(55-110) < 0.005
Table 3 Intra and post operative complications in the
two groups
Abdominal surgery
(n = 37)%
Vaginal surgery
(n = 31)%
p value
Intraoperative
complications
NS
Bleeding 1 1
Postoperative
complications
NS
Bleeding 1 1
Lymphorrea 1 -
Pelvic infection - 2
Deep Venous
Thrombosis
1-
Table 4 Clinical and pathologic data relating to 68
patients undergoing vaginal or laparotomic surgery for
endometrial cancer
Abdominal surgery
(n = 37)%
Vaginal surgery
(n = 31)%
p
value
Mean age(years) 70.4 (± 4.2SD) 76.2(± 5.6SD)
FIGO stage NS
IA 1(2.7%) 10(32.3%)
IB 22(59.5%) 14 (45.2%)
IC 11(29.7%) 6(19.4%)
IIA 1(2.7%) 1(3.2%)
IIB 2(5.4%) -
Histological Grade NS
G1 4(10.8%) 8(25.8%)
G2 18(48.6%) 21(67.7%)
G3 15(40.5%) 2(6.5%)
Myometrial depth
invasion
0.03
M1(< 50%) 23(62.2%) 29(93.5%)
M2(> 50%) 14(37.8%) 2(6.5%)
Adjuvant RT 0.04
Yes 14(20.5%) 8(11.7%)
No 23(33.8%) 23(33.8%)
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Page 3 of 6and V respectively (NS) (Figure 2). Disease-specific sur-
vival at 5-years was 97% for both groups (NS) (Figure 3).
Conclusions
Endometrial cancer accounts for the 7% of all women’s
cancer. Prognostic features are well defined. They
include race, FIGO stage, tumor grade, depth of myo-
metrial invasion, metastatic disease to pelvic and/or
para-aortic nodes, cervical or adnexal involvement,
histologic sub-types, presence of LVSI, DNA aneuploidy.
FIGO stage is critical [4].
Current gold standard for both staging and treatment is
surgery. It includes thorough exploration of the abdom-
inal-pelvic cavity, pelvic washing, hysterectomy, bilateral
salpingo-oophorectomy and pelvic and para-aortic lym-
phadenectomy. Alternative approaches include vaginal
hysterectomy with vaginal bilateral salpingo-oophorect-
omy, first line radiation therapy and endocrine therapies
[10,11]. Laparoscopic surgery is been progressively inte-
grated into standard endometrial cancer care during the
past years. Beside the well-known advantages, it is still
unfit for patients who are poor candidates for general
anesthesia. Age and obesity are relative contraindications.
Difficulties in establishing pneumo-peritoneum and ven-
tilation, poorer visualization, inability to tolerate Trende-
lenburg position are common problems encountered
with obese patients. Laparoscopic surgery should be per-
formed with an acceptable rate of complications to be a
viable option, therefore it was not considered for group V
women. Moreover, since data on long-term follow-up
and recurrences are still unclear, it was preferred a com-
parison with standard abdominal procedure.
It is been cleared that a clinical, non surgical,
approach has a very high risk of failure.
Elderly patients have a higher prevalence of comorbid-
ities as obesity, diabetes mellitus, hypertension, CAD
[12]. Thus, surgical risk for abdominal procedures is
eventually higher among these patients and vaginal sur-
gery appears safer. Nevertheless, it does not allow
exploration of peritoneal contents. Therefore, an assess-
ment of lymph nodal status is unachievable.
Figure 1 Overall survival.
Comparison of survival curves (Logrank test) 
Chi-square = 0.002006 
DF = 1 
Significance      P = 0.9643 
Figure 2 Disease-free survival.
Figure 3 Disease specific survival.
Moscarini et al. World Journal of Surgical Oncology 2011, 9:74
http://www.wjso.com/content/9/1/74
Page 4 of 6Obese women with high-level estrogens usually harbor
a cancer diagnosed at an early stage, mostly IA or IB.
Trimble et al. stated that lymphadenectomy in patients
with a stage IA or IB do not provide a clear survival
benefit [13]. 514 patients with early stage endometrial
c a r c i n o m aw e r ec o n s i d e r e di nas t u d yt oa s s e s st h er o l e
of systematic pelvic lymphadenectomy in improving sur-
vival rates. Surgical staging is statistically improved by
this procedure while overall and disease-free survival is
not different from patients who do not undergo a pelvic
node dissection [14]. Recent prospective randomized
trials as ASTEC claimed to unveil the nebulous scenario
that surrounds lymph nodal dissection in endometrial
cancer surgery [15].
The role of lymphadenectomy is still debated, since
surgical staging procedures were incomplete and authors
failed to assess the para-aortic area [16]. The recent
revision of 1988 FIGO staging does not clarify whether
a lymph nodal dissection should be performed or not.
This is because a clear assessment of which patient
should be considered low-risk or high-risk is still miss-
ing. Moreover, a standardization of lymph node dissec-
tion appears to be necessary. A standardized procedure
should include a precise definition of the anatomic mar-
gins and specify the extent of dissection, as well as state
clearly how many lymph nodes should be harvested.
In our study, we assessed survival rates in a popula-
tion of elderly patients with early stage endometrial can-
cer, who presented a higher surgical risk. These patients
underwent a vaginal hysterectomy in place of the stan-
dard abdominal procedure. Comparing this approach to
the traditional procedure used in a control group, we
got evidences of high-cure rate achieved in elderly
patients with the vaginal technique (> 70 years old).
This evidence has been confirmed in other series in lit-
erature [7,17].
A follow-up of at least 3 years showed that medium-
term survival of both groups was similar.
Patients who underwent vaginal hysterectomy pre-
sented massive obesity (BMI > 40 kg/m2), hypertension
and diabetes mellitus more frequently than other group
patients (p < 0.005). Intra-operative complications were
not statistically significantly different between the two
groups. Controls had a higher frequency of post-opera-
tive complications, probably related to the more exten-
sive procedure. Mean hospital stay and operative times
were significantly lower for group V.
Results show how vaginal surgery associated or not to
adjuvant radiation therapy is a feasible and valid
approach in elderly patients with comorbidities and
early-stage of the disease.
Vaginal surgery could therefore be the proper choice
in selected patients with early stages and lower surgical
risk [18], in addition to the elderly patient exposed to a
higher surgical risk.
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